Related Experiment Video

Updated: Aug 1, 2026

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

11.9K

A Phase 3 Trial of Resmetirom in NASH with Liver Fibrosis. Reply

Stephen A Harrison1, Rebecca Taub2

  • 1Pinnacle Clinical Research, San Antonio, TX sharrison@pinnacleresearch.com.

The New England Journal of Medicine
|May 1, 2024
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

3D Imaging of the Liver Extracellular Matrix in a Mouse Model of Non-Alcoholic Steatohepatitis
06:46

3D Imaging of the Liver Extracellular Matrix in a Mouse Model of Non-Alcoholic Steatohepatitis

Published on: February 25, 2022

1.9K
Author Spotlight: Advancing Hepatic Fibrosis Diagnosis Using Magnetic Resonance Elastography and AI
06:09

Author Spotlight: Advancing Hepatic Fibrosis Diagnosis Using Magnetic Resonance Elastography and AI

Published on: July 21, 2023

1.2K

Related Experiment Videos

Last Updated: Aug 1, 2026

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

11.9K
3D Imaging of the Liver Extracellular Matrix in a Mouse Model of Non-Alcoholic Steatohepatitis
06:46

3D Imaging of the Liver Extracellular Matrix in a Mouse Model of Non-Alcoholic Steatohepatitis

Published on: February 25, 2022

1.9K
Author Spotlight: Advancing Hepatic Fibrosis Diagnosis Using Magnetic Resonance Elastography and AI
06:09

Author Spotlight: Advancing Hepatic Fibrosis Diagnosis Using Magnetic Resonance Elastography and AI

Published on: July 21, 2023

1.2K

Related Concept Videos

Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...

Articles linked to this work by shared authors, journal, and citation graph.

Prospective validation of imaging and serum diagnostic biomarkers of steatohepatitis and fibrosis in MASLD: the LITMUS Imaging Study.

Nature medicine·2026

Uncovering the genetic basis of crown rust resistance in a northern-by-southern oat biparental population.

PloS one·2026

Assessment of Esophageal and Gastric Varices in Patients With Cirrhosis for Clinical Trials: A Centralized Blinded Evaluation System.

Gastro hep advances·2026

Efficacy and safety of belapectin for the prevention of esophageal varices in patients with MASH cirrhosis: The randomized, placebo-controlled NAVIGATE trial.

Hepatology (Baltimore, Md.)·2026

Quantitative regression of qFibrosis with resmetirom: Exploratory histologic endpoints from the MAESTRO-NASH phase III clinical trial.

Journal of hepatology·2026

Diagnostic Performance of LIVERFASt as a Non-invasive Liver Fibrosis Test: Data from Three Cohorts of Patients with Metabolic Dysfunction-associated Steatotic Liver Disease.

Journal of gastrointestinal and liver diseases : JGLD·2025

Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes.

The New England journal of medicine·2026

Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity.

The New England journal of medicine·2026

Giredestrant plus Everolimus in Advanced Breast Cancer.

The New England journal of medicine·2026

Effect of Donor Seminal Plasma on Sperm Functional Parameters in Male Infertility.

Bulletin of experimental biology and medicine·2026

Multi-omic analysis reveals maturation programs in human pluripotent stem cell-derived cardiomyocytes during long-term culture.

Journal of molecular and cellular cardiology·2026

Excellent response to high-dose Riboflavin in Brown-Vialetto-Van Laere syndrome: A case report.

Medicine·2026

No Significant Difference in Cost or Outcomes at 1-Year Minimum Follow-Up After Arthroscopic Partial Meniscectomy Comparing 1.9 mm Distal Chip-on-Tip Needlescope Versus 4 mm Glass Rod Lens Arthroscope: Both Treatments Are Highly Cost-Effective.

Arthroscopy, sports medicine, and rehabilitation·2026

Early Cost Analysis of Middle Meningeal Artery Embolization for Chronic Subdural Hematoma Treatment: A National Claims Database Analysis (MarketScan, 2007-2023).

Cureus·2026

Myogenic differentiation-derived small extracellular vesicles as a therapeutic strategy for miR-193b-3p-mediated muscle regeneration.

Molecular therapy. Nucleic acids·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us